Treatment of breast cancer during pregnancy: an observational study - PubMed (original) (raw)
Clinical Trial
doi: 10.1016/S1470-2045(12)70261-9. Epub 2012 Aug 16.
Sileny N Han, Gunter von Minckwitz, Marijke Bontenbal, Alistair Ring, Jerzy Giermek, Tanja Fehm, Kristel Van Calsteren, Sabine C Linn, Bettina Schlehe, Mina Mhallem Gziri, Pieter J Westenend, Volkmar Müller, Liesbeth Heyns, Brigitte Rack, Ben Van Calster, Nadia Harbeck, Miriam Lenhard, Michael J Halaska, Manfred Kaufmann, Valentina Nekljudova, Frederic Amant
Affiliations
- PMID: 22902483
- DOI: 10.1016/S1470-2045(12)70261-9
Clinical Trial
Treatment of breast cancer during pregnancy: an observational study
Sibylle Loibl et al. Lancet Oncol. 2012 Sep.
Abstract
Background: Little is known about the treatment of breast cancer during pregnancy. We aimed to determine whether treatment for breast cancer during pregnancy is safe for both mother and child.
Methods: We recruited patients from seven European countries with a primary diagnosis of breast cancer during pregnancy; data were collected retrospectively if the patient was diagnosed before April, 2003 (when the registry began), or prospectively thereafter, irrespective of the outcome of pregnancy and the type and timing of treatment. The primary endpoint was fetal health for up to 4 weeks after delivery. The registry is ongoing. The study is registered with ClinicalTrials.gov, number NCT00196833.
Findings: From April, 2003, to December, 2011, 447 patients were registered, 413 of whom had early breast cancer. Median age was 33 years (range 22-51). At the time of diagnosis, median gestational age was 24 weeks (range 5-40). 197 (48%) of 413 women received chemotherapy during pregnancy with a median of four cycles (range one to eight). 178 received an anthracycline, 15 received cyclophosphamide, methotrexate, and fluorouracil, and 14 received a taxane. Birthweight was affected by chemotherapy exposure after adjustment for gestational age (p=0·018), but not by number of chemotherapy cycles (p=0·71). No statistical difference between the two groups was observed for premature deliveries before the 37th week of gestation. 40 (10%) of 386 infants had side-effects, malformations, or new-born complications; these events were more common in infants born before the 37th week of gestation than they were in infants born in the 37th week or later (31 [16%] of 191 infants vs nine [5%] of 195 infants; p=0·0002). In infants for whom maternal treatment was known, adverse events were more common in those who received chemotherapy in utero compared with those who were not exposed (31 [15%] of 203 vs seven [4%] of 170 infants; p=0·00045). Two infants died; both were exposed to chemotherapy and delivered prematurely, but both deaths were thought not to be related to treatment. Median disease-free survival for women with early breast cancer was 70·6 months (95% CI 62·1-105·5) in women starting chemotherapy during pregnancy and 94·4 months (lower 95% CI 64·4; upper 95% CI not yet reached) in women starting chemotherapy after delivery (unadjusted hazard ratio 1·13 [95% CI 0·76-1·69]; p=0·539).
Interpretation: Although our data show that infants exposed to chemotherapy in utero had a lower birthweight at gestational age than did those who were unexposed, and had more complications, these differences were not clinically significant and, since none of the infants was exposed to chemotherapy in the first trimester, were most likely related to premature delivery. Delay of cancer treatment did not significantly affect disease-free survival for mothers with early breast cancer. Because preterm birth was strongly associated with adverse events, a full-term delivery seems to be of paramount importance.
Funding: BANSS Foundation, Biedenkopf, Germany and the Belgian Cancer Plan, Ministry of Health, Belgium.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Comment in
- Increased evidence for use of chemotherapy in pregnancy.
Mir O, Berveiller P. Mir O, et al. Lancet Oncol. 2012 Sep;13(9):852-4. doi: 10.1016/S1470-2045(12)70331-5. Epub 2012 Aug 16. Lancet Oncol. 2012. PMID: 22902484 No abstract available. - Breast cancer: Cancer in pregnancy, to treat or not to treat?
Villanueva MT. Villanueva MT. Nat Rev Clin Oncol. 2012 Oct;9(10):549. doi: 10.1038/nrclinonc.2012.157. Epub 2012 Sep 11. Nat Rev Clin Oncol. 2012. PMID: 22965152 No abstract available.
Similar articles
- Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry.
Cardonick E, Usmani A, Ghaffar S. Cardonick E, et al. Am J Clin Oncol. 2010 Jun;33(3):221-8. doi: 10.1097/COC.0b013e3181a44ca9. Am J Clin Oncol. 2010. PMID: 19745695 - Breast cancer during pregnancy: maternal and fetal outcomes.
Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Cardonick E, et al. Cancer J. 2010 Jan-Feb;16(1):76-82. doi: 10.1097/PPO.0b013e3181ce46f9. Cancer J. 2010. PMID: 20164696 - Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study.
Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, Willemsen MA, Kapusta L, Van Calster B, Wouters H, Heyns L, Han SN, Tomek V, Mertens L, Ottevanger PB. Amant F, et al. Lancet Oncol. 2012 Mar;13(3):256-64. doi: 10.1016/S1470-2045(11)70363-1. Epub 2012 Feb 10. Lancet Oncol. 2012. PMID: 22326925 - Two cases of breast carcinoma during pregnancy and review of the literature.
Pascual O, Uriarte M, Agustín MJ, Gimeno V, Larrodé I, Abad MR. Pascual O, et al. J Oncol Pharm Pract. 2016 Aug;22(4):652-6. doi: 10.1177/1078155215587540. Epub 2015 May 26. J Oncol Pharm Pract. 2016. PMID: 26018968 Review. - Gastric cancer during pregnancy: A report on 13 cases and review of the literature with focus on chemotherapy during pregnancy.
Maggen C, Lok CA, Cardonick E, van Gerwen M, Ottevanger PB, Boere IA, Koskas M, Halaska MJ, Fruscio R, Gziri MM, Witteveen PO, Van Calsteren K, Amant F; International Network on Cancer, Infertility and Pregnancy (INCIP). Maggen C, et al. Acta Obstet Gynecol Scand. 2020 Jan;99(1):79-88. doi: 10.1111/aogs.13731. Epub 2019 Oct 16. Acta Obstet Gynecol Scand. 2020. PMID: 31529466 Free PMC article. Review.
Cited by
- Breast cancer in pregnancy: a comprehensive review of diagnosis, management, and outcomes.
Mumtaz A, Otey N, Afridi B, Khout H. Mumtaz A, et al. Transl Breast Cancer Res. 2024 Jul 25;5:21. doi: 10.21037/tbcr-24-26. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 39184929 Free PMC article. Review. No abstract available. - Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer.
Cifuentes C, Oeste CL, Fernández-Pisonero I, Hortal AM, García-Macías C, Hochart J, Rubira R, Horndler L, Horndler C, Bustelo XR, Alarcón B. Cifuentes C, et al. Mol Cancer. 2024 Jul 10;23(1):142. doi: 10.1186/s12943-024-02054-3. Mol Cancer. 2024. PMID: 38987766 Free PMC article. - Obstetric and neonatal outcomes following taxane use during pregnancy: a systematic review.
Aranda-Gutierrez A, Ferrigno Guajardo AS, Vaca-Cartagena BF, Gonzalez-Sanchez DG, Ramirez-Cisneros A, Becerril-Gaitan A, Azim HA Jr, Villarreal-Garza C. Aranda-Gutierrez A, et al. BMC Cancer. 2024 Jan 2;24(1):9. doi: 10.1186/s12885-023-11704-6. BMC Cancer. 2024. PMID: 38166767 Free PMC article. - Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients.
Bergamini C, Cavalieri S, Resteghini C, Alfieri S, Nuzzolese I, Colombo E, Ottini A, Calareso G, Vingiani A, Iacovelli NA, Franceschini M, Guzzo M, Deganello A, Licitra L. Bergamini C, et al. Front Oncol. 2023 Nov 22;13:1298439. doi: 10.3389/fonc.2023.1298439. eCollection 2023. Front Oncol. 2023. PMID: 38074678 Free PMC article. - Cancer in pregnancy - The obstetrical management.
Storgaard L, Greiber IK, Pedersen BW, Nielsen BB, Karlsen MA. Storgaard L, et al. Acta Obstet Gynecol Scand. 2024 Apr;103(4):630-635. doi: 10.1111/aogs.14653. Epub 2023 Aug 18. Acta Obstet Gynecol Scand. 2024. PMID: 37596726 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous